What is Global Recombinant Human Coagulation VIIa Market?
The Global Recombinant Human Coagulation VIIa Market is a specialized sector within the pharmaceutical industry that focuses on the production and distribution of Recombinant Human Coagulation VIIa, a genetically engineered version of a naturally occurring protein that plays a crucial role in the blood clotting process. This market has significant implications for the treatment of various bleeding disorders, particularly hemophilia, a condition characterized by the body's inability to form blood clots effectively. The market's value stood at US$ 1133.8 million in 2022, and it is projected to reach US$ 1467.3 million by 2029, growing at a compound annual growth rate (CAGR) of 3.7% during the forecast period from 2023 to 2029.
Prefilled Syringe, Vial in the Global Recombinant Human Coagulation VIIa Market:
The Global Recombinant Human Coagulation VIIa Market is dominated by Novo Nordisk, a Danish multinational pharmaceutical company that holds a market share of over 95%. The market is segmented based on the type of packaging used for the product, with prefilled syringes accounting for over 78% of the market share. Prefilled syringes offer several advantages over traditional vials, including ease of use, reduced risk of contamination, and improved dosing accuracy. However, vials continue to be used in certain settings, particularly in hospitals and clinics where multiple doses may be required.
Congenital Hemophilia, Acquired Hemophilia, Others in the Global Recombinant Human Coagulation VIIa Market:
North America is the most significant consumer market for Recombinant Human Coagulation VIIa, accounting for approximately 45% of the global market share. This can be attributed to the high prevalence of bleeding disorders in the region, coupled with the availability of advanced healthcare infrastructure and the presence of key market players. However, other regions, including Europe and Asia-Pacific, are also witnessing steady growth in the consumption of Recombinant Human Coagulation VIIa, driven by increasing awareness about bleeding disorders and improvements in healthcare facilities.
Global Recombinant Human Coagulation VIIa Market Outlook:
In terms of application, the Global Recombinant Human Coagulation VIIa Market is primarily driven by the treatment of congenital hemophilia, which accounts for about 65% of the market share. Congenital hemophilia is a genetic disorder that impairs the body's ability to make blood clots, leading to prolonged bleeding after injury or surgery. Recombinant Human Coagulation VIIa is used to replace the missing or deficient clotting factor, thereby helping to control and prevent bleeding episodes. Other applications of Recombinant Human Coagulation VIIa include the treatment of acquired hemophilia and other bleeding disorders.
| Report Metric | Details |
| Report Name | Recombinant Human Coagulation VIIa Market |
| Accounted market size in 2023 | US$ 1179.9 million |
| Forecasted market size in 2029 | US$ 1467.3 million |
| CAGR | 3.7 |
| Base Year | 2023 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Segment by Region |
|
| By Company | Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
